Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED)’s share price traded down 4.9% during trading on Thursday after an insider sold shares in the company, AnalystRatingsNetwork reports. The company traded as low as $17.50 and last traded at $17.80, with a volume of 142,177 shares. The stock had previously closed at $18.72.

Specifically, EVP John A. Lewicki sold 2,191 shares of Oncomed Pharmaceuticals stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $20.01, for a total value of $43,841.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at BMO Capital Markets reiterated a “hold” rating on shares of Oncomed Pharmaceuticals in a research note on Thursday, August 28th. Separately, analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Finally, analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $37.00.

The stock has a 50-day moving average of $20.48 and a 200-day moving average of $25.57. The company’s market cap is $528.7 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last released its earnings data on Thursday, August 7th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. Analysts expect that Oncomed Pharmaceuticals will post $-1.35 EPS for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.